medigraphic.com
ISSN 0016-3813 (Impreso)

2004, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2004; 140 (6)


Cuidados del paciente cardiópata tras una intervención coronaria percutánea

Barrera-Ramírez CF, Pineda PLR, Guzmán CE

Idioma: Español
Referencias bibliográficas: 69
Paginas: 619-627
Archivo PDF: 478.85 Kb.


RESUMEN

En la actualidad, las indicaciones y alcances de la cardiología intervencionista permiten que cada vez más pacientes puedan ser revascularizados mediante intervenciones coronarias percutáneas. Es esencial para los médicos que están en contacto o tienen a su cargo el cuidado de estos pacientes conocer los beneficios, características y riesgos del procedimiento. En este trabajo revisamos los conceptos generales actuales de la angioplastía coronaria.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Forssman W. Klin Worach; 1929. Citado en: Martínez-Ríos MA, Gil Moreno M, Turnero G, Galante CJ, Gutiérrez Fuster E, editores. Generalidades del cateterismo cardíaco. En: Martínez-Ríos E, editor. Cateterismo cardíaco. Diagnóstico y tratamiento de la cardiopatias. México: Ed. Trillas;1990. pp. 19-38.

  2. Martínez-Ríos MA, Gil Moreno M, Turnero G, Galante CJ, Gutiérrez Fuster E. Generalidades del cateterismo cardíaco. En: Martínez-Ríos E, editor. Cateterismo cardíaco. Diagnóstico y tratamiento de la cardiopatías. México; Ed. Trillas;1990. pp. 19-38.

  3. Delcán JL. Del cateterismo diagnóstico a la cardiología intervencionista. MApfre Med 1995;6(Supl II):7-8.

  4. Grüentzig AR. Traslumination dilatation of coronary artery stenosis. Lancet 1978;I:263.

  5. García EJ. Utilidad clínica del stent coronario. Mapfre Med 1995;6(Supl II):28-36.

  6. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-20.

  7. Serruys PW, Strauss BH, van Beusekom HM, van der Giessen WJ. Stenting of coronary arteries: has a modern Pandora's box been opened? J Am Coll Cardiol 1991;17(6 Suppl B):143B-154B.

  8. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13-17.

  9. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.

  10. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331(8):489-495.

  11. Macaya C, Iñiguez RA, Goicolea RJ. Papel de la aterectomía coronaria (de Simpson, de extracción y de rotación en la revascularización miocárdica) Mapfre Med 1995;Supl II:15-27.

  12. Grech ED. Percutaneous coronary intervention. I: History and development. Br Med J 2003;326:1080-82.

  13. Linnemeier TJ. The hot and cold issues of laser angioplasty. Cathet Cardiovasc Diag 1992;27:1-4.

  14. Margolis JR, Mehta S. Excimer laser coronary angioplasty. Am J Cardiol 1992;69:3F-11F.

  15. Warth DC, Leon MB, O'Neill W, Zacca N, Polissar NL, Buchbinder M. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994;24:641-648.

  16. Jain D, Schäfer U, Debdorfer A, Kurz T, Lindemann C, Tölg R, et al. Neurohumoral activation in percutaneous coronary interventions: apropos of ten vasoactive substances during and immediately following coronary rotastenting. Indian Heart J 2001;53:301-307.

  17. Brogan WC III, Popma JJ, Pichard AD, Satler LW, Kent KM, Mintz GS, et al. Rotational coronary atherectomy after unsuccessful coronary balloon angioplasty. Am J Cardiol 1993;71:794-798.

  18. Solomon R, Werner C, Mann D, Elia J, Silva P. Effects of saline, manitol and furosemide to prevent acute decrease in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-420.

  19. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE Study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol 1999;33:403-411.

  20. Barrera-Ramírez CF, Jiménez-Mazuecos J, Alfonso F. Apical thrombus associated with left ventricular apical ballooning. Heart 2003;89:927.

  21. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003;58:28-35.

  22. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-16672.

  23. Jin J, Daniel J, Kunapuli S. Molecular basis for ADP induced platelet aggregation: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273:2030-2034.

  24. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.

  25. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.

  26. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998;98:2126-2132.

  27. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998;98:1597-1603.

  28. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-544.

  29. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-2528.

  30. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999;281:806-810.

  31. Barrera-Ramírez CF, Fernández-Ortiz A, Angiolillo DJ, Bernardo E, Viveros M, Fantidis P, Soto H, Alfonso F, Escaned J, Macaya C. Baseline platelet function in low responders to antiplatelet treatment following coronary stent implantation. Circulation 2002 November;106(19)Suppl II:517.

  32. Kolansky DM, Klugherz BD, Curran SC, Herrmann HC, Magness K, Wilensky RL, et al. Combination therapy with clopidogrel and aspirin after coronary stenting. Catheter Cardiovasc Interv 2000;50:276-279.

  33. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW. Metaanalysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.

  34. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronaryartery stents. Circulation 2000;101:590-593.

  35. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-629.

  36. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366-1370.

  37. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001;103:1403-1409.

  38. Berger PB. Results of the Ticlid or Plavix Post-Stents (TOPPS) Trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr Control Trials Cardiovasc Med 2000;1(2):83-87.

  39. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE Study. Lancet 2001;358:527-533.

  40. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE). N Engl J Med 2001;345:494-502.

  41. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 2002;288:2411-2420.

  42. Ross R. The pathogenesis of atherosclerosis- an update. N Engl J Med 1986;314:488-500.

  43. Cassar K, Bachoo P, Brittenden J. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996;Suppl 4:269-284.

  44. Lecompte T. Thrombogenese arterielle: le role decisif des plaquettes. Arch Mal Coeur Vaiss 2002;95(Spec No 7):7-9.

  45. Flores NA. Las plaquetas y la enfermedad cardíaca: ¿Cuánto más puede la ciencia básica influir en la práctica clínica? Arch Inst Cardiol Mex 2000;70:213-218.

  46. De la Llata Romero M, Vargas CM, Magaña Serrano JA, Leal CC, Férez Santander S, Lupi Herrera E, et al. El Registro Nacional de las Intervenciones Coronarias Percutáneas (RNCIP). Arch Cardiol Mex 2003;73:304-312.

  47. Hernández JM, Goicolea J, Durán JM, Augé JM. Resgistro español de hemodinámica y cardiología intervensionista. XII Informe oficial de la sección de hemodinámica y cardiología intervensionista de la Sociedad Española de Cardiología. Rev Esp Cardiol 2003;56:1105-1118.

  48. Hernández JM, Goicolea J, Durán JM, Augé JM. Registro de actividad de las secciones de hemodinámica y cardiología intervencionista de la sociedad española de cardiología. Rev Esp Cardiol 2001;54:1426-438.

  49. Harrell L, Schunkert H, Palacios I. Risk predictors in patients scheduled for percutaneous coronary revascularization. Cathet Cardiovasc Interv 1999;48:253-60.

  50. Barrera-Ramírez CF, Oseguera J. Taponamiento cardíaco. En: Manual de Urgencias del Instituto Nacional de la Nutrición Salvador Zubirán. México, D.F.: McGrawHill;2000. p. 927.

  51. Grech ED. Percutaneous coronary intervention. II: The procedure. Br Med J 2003;326:1137-1140.

  52. Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary angioplasty procedure volume and major complications. JAMA 1995;274:1137-42.

  53. Esplugas Oliveras E, Hernández Antolín R, López Bescos L, Moreu Burgos J, Pomar Moya-Prats JL. The performance of coronary angioplasties at centres without cardiac surgery. The Recommendations of the Sociedad Española de Cardiología. Rev Esp Cardiol 1999;52:5-12.

  54. Martínez-Ríos MA, Eid-Lidt G, Luna Guerra J, Villavicencio Fernández R, Ban Hayashi E, et al. The benefit of a coronary stent in the reduction of major cardiac complications in acute coronary síndromes. Arch Inst Cardiol Mex 1999;69:121-6.

  55. Alfonso F, Flores A, Escaned J, Sanmartín M, Hernández R, Fernández-Ortiz A, Bañuelos C, et al. Pressure wire kinking, entanglement, and entrapment during intravascular ultrasound studies: a potentially dangerous complication. Catheter Cardiovasc Interv 2000;50:221-5.

  56. Soriano J, Alfonso F, Cequier A, Moris C. The Registry of the Activities of the Hemodynamics and Interventional Cardiology Section in 1998. Rev Esp Cardiol 1999;52:1105-20.

  57. Gaspar J, Ban Hayashi E, Villavicencio R, de la Garza PJ, Gil GM, Martínez-Ríos MA. The primary outcome in transluminal coronary angioplasty: the recent experience of the Instituto Nacional de Cardiología (1991-1992). Arch Inst Cardiol Mex 1992;62:499-505.

  58. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stents with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.

  59. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part 1. Circulation 2003;107:2274-2279.

  60. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres, Pinto IM, et al. Lack of Neointimal Proliferation after Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation 2001 Jan 16;103(2):192-195.

  61. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 Jun 6;346(23):1773-1780.

  62. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R. New approaches to preventing restenosis. Br Med J 2003 Aug 2;327(7409):274-279.

  63. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003 Jan 7;107(1):38-42.

  64. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004 Jan 20;109(2):196-200.

  65. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shauhnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.

  66. Kereiakes DJ. Hippocrates revisited. The evidence for drug-eluting stents. Circulation 2003;1073012-14.

  67. Angiolillo DJ, Sabate M. Paasato, presente e futuro della brachiterapia intracoronarica. Ital Heart J Suppl 2003;4:794-796.

  68. O'Neill WW, Leon MB. Drug-eluting stents. Costs versus clinical benefit. Circulation 2003;107:3008.

  69. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004 Jan 20;109(2):190-195.




2020     |     www.medigraphic.com